Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175-201; PMID:23297039; http://dx.doi.org/10.1093/jnci/djs491
   PubMed Web of Science ®Google Scholar
• Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Sem Cancer Biol 1999; 9:67-81; PMID:10202129; http://dx.doi.org/10.1006/scbi.1998.0119
   PubMed Web of Science ®Google Scholar
• Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signalling 2009; 21:665-74; PMID:19167485; http://dx.doi.org/10.1016/j.cellsig.2009.01.006
   PubMed Web of Science ®Google Scholar
• Gangopadhyay A, Lazure D, Thomas P. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells. Clin Exp Metast 1998; 16:703-12; PMID:10211983; http://dx.doi.org/10.1023/A:1006576627429
   PubMed Web of Science ®Google Scholar
• Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57:327-34; PMID:2702691; http://dx.doi.org/10.1016/0092-8674(89)90970-7
   PubMed Web of Science ®Google Scholar
• Network NCC. Rectal Cancer. NCCN Clin Practice Guidelines in Oncol (NCCN Guidelines ®), 2015
   Google Scholar
• Boey J, Cheung HC, Lai CK, Wong J. A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma. World J Surg 1984; 8:279-86; PMID:6464483; http://dx.doi.org/10.1007/BF01655052
   PubMed Web of Science ®Google Scholar
• Arnaud JP, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum 1980; 23:141-4; PMID:7379666; http://dx.doi.org/10.1007/BF02587615
   PubMed Web of Science ®Google Scholar
• Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, Fletcher WS, Cruz AB Jr, Gatchell FG, Oviedo M, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55:1284-90; PMID:3971297; http://dx.doi.org/10.1002/1097-0142(19850315)55:6%3c1284::AID-CNCR2820550622%3e3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• McCall JL, Black RB, Rich CA, Harvey JR, Baker RA, Watts JM, Toouli J. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994; 37:875-81; PMID:8076486; http://dx.doi.org/10.1007/BF02052591
   PubMed Web of Science ®Google Scholar
• Hine KR, Dykes PW. Serum CEA testing in the post-operative surveillance of colorectal carcinoma. Br J Cancer 1984; 49:689-93; PMID:6733018; http://dx.doi.org/10.1038/bjc.1984.109
   PubMed Web of Science ®Google Scholar
• Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987; 47:5501-3; PMID:3308077
   PubMed Web of Science ®Google Scholar
• Malaguarnera G, Giordano M, Paladina I, Rando A, Uccello M, Basile F, Biondi A, Carnazzo S, Alessandria I, Mazzarino C. Markers of bile duct tumors. World J Gastrointest Oncol 2011; 3:49-59; PMID:21528090; http://dx.doi.org/10.4251/wjgo.v3.i4.49
   PubMed Web of Science ®Google Scholar
• Ohuchi N, Takahashi K, Matoba N, Sato T, Taira Y, Sakai N, Masuda M, Mori S. Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 1989; 19:242-8; PMID:2810823
   PubMed Web of Science ®Google Scholar
• Yamaguchi A, Kurosaka Y, Ishida T, Nishimura G, Kanno M, Kosaka T, Yonemura Y, Miyazaki I. Clinical significance of tumor marker NCC-ST 439 in large bowel cancers. Dis Colon Rectum 1991; 34:921-4; PMID:1914727; http://dx.doi.org/10.1007/BF02049709
   PubMed Web of Science ®Google Scholar
• Iemura K, Moriya Y. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma. Eur J Surg Oncol 1993; 19:439-42; PMID:8405479
   PubMedGoogle Scholar
• Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000; 20:5195-8; PMID:11326694
   PubMed Web of Science ®Google Scholar
• Filella X, Molina R, Pique JM, Garcia-Valdecasas JC, Grau JJ, Novell F, Astudillo E, de Lacy A, Daniels M, Ballesta AM. Use of CA 19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA. Tumour Biol 1994; 15:1-6; PMID:8146525; http://dx.doi.org/10.1159/000217867
   PubMed Web of Science ®Google Scholar
• Bast RC Jr., Ravdin P, Hayes DF, Bates S, Fritsche H Jr., Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1865-78; PMID:11251019
   PubMed Web of Science ®Google Scholar
• Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14:2843-77; PMID:8874347
   PubMed Web of Science ®Google Scholar
• Araujo RL, Gonen M, Allen P, DeMatteo R, Kingham P, Jarnagin W, D'Angelica M, Fong Y. Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases. Ann Surg Oncol 2015; Epub ahead of print; PMID:25582745
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr, ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313-27; PMID:17060676; http://dx.doi.org/10.1200/JCO.2006.08.2644
   PubMed Web of Science ®Google Scholar
• Yakabe T, Nakafusa Y, Sumi K, Miyoshi A, Kitajima Y, Sato S, Noshiro H, Miyazaki K. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol 2010; 17:2349-56; PMID:20217258; http://dx.doi.org/10.1245/s10434-010-1004-5
   PubMed Web of Science ®Google Scholar
• Kawamura YJ, Tokumitsu A, Mizokami K, Sasaki J, Tsujinaka S, Konishi F. First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs. Clin Colorectal Cancer 2010; 9:48-51; PMID:20100688; http://dx.doi.org/10.3816/CCC.2010.n.006
   PubMed Web of Science ®Google Scholar
• Caglar M, Yener C, Karabulut E. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer. Int J Comput Assist Radiol Surg 2015; Jul;10(7):993-1002. PMID:25213271; http://dx.doi.org/10.1007/s11548-014-1115-8
   PubMed Web of Science ®Google Scholar
• Tampellini M, Ottone A, Alabiso I, Baratelli C, Forti L, Berruti A, Aroasio E, Scagliotti GV. The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. Tumour Biol 2014; 36:1519-27; PMID:25374062; http://dx.doi.org/10.1007/s13277-014-2693-3
   PubMed Web of Science ®Google Scholar
• Hachiya T, Koyama S, Kubo K, Sekiguchi M, Honda T. Elevated serum CA19-9 level and regional lymphadenopathy in a young man with allergic bronchopulmonary aspergillosis. Intern Med 1998; 37:91-3; PMID:9510409; http://dx.doi.org/10.2169/internalmedicine.37.91
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Kobayashi S, Tanaka M, Akimoto T, Takasaki Y. [Serum CA 19-9 levels in rheumatic diseases with interstitial pneumonia]. Nihon Rinsho Meneki Gakkai Kaishi 1996; 19:128-35; PMID:8705689; http://dx.doi.org/10.2177/jsci.19.128
   PubMedGoogle Scholar
• McLaughlin R, O'Hanlon D, Kerin M, Kenny P, Grimes H, Given HF. Are elevated levels of the tumour marker CA19-9 of any clinical significance?–an evaluation. Irish journal of medical science 1999; 168:124-6; PMID:10422394; http://dx.doi.org/10.1007/BF02946481
   PubMed Web of Science ®Google Scholar
• Halme L, Karkkainen P, Isoniemi H, Makisalo H, von Bogulawski K, Hockerstedt K. Carbohydrate 19-9 antigen as a marker of non-malignant hepatocytic ductular transformation in patients with acute liver failure. A comparison with alpha-fetoprotein and carcinoembryonic antigen. Scand J Gastroenterol 1999; 34:426-31; PMID:10365905
   PubMed Web of Science ®Google Scholar
• Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999; 10 Suppl 4:145-9; PMID:10436809; http://dx.doi.org/10.1093/annonc/10.suppl_4.S145
   PubMed Web of Science ®Google Scholar